S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:MNPR

Monopar Therapeutics (MNPR) Stock Forecast, Price & News

$0.58
+0.01 (+1.30%)
(As of 05:19 PM ET)
Compare
Today's Range
$0.55
$0.60
50-Day Range
$0.57
$0.87
52-Week Range
$0.53
$4.88
Volume
6,049 shs
Average Volume
194,893 shs
Market Capitalization
$8.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.33

Monopar Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
1,888.3% Upside
$11.33 Price Target
Short Interest
Healthy
1.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Monopar Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.76) to ($0.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars


MNPR stock logo

About Monopar Therapeutics (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

MNPR Price History

MNPR Stock News Headlines

U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Expert Ratings for Monopar Therapeutics
Monopar Therapeutics Inc (MNPR) Gets a Buy from H.C. Wainwright
10-Q: MONOPAR THERAPEUTICS
See More Headlines
Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MNPR Company Calendar

Last Earnings
8/10/2023
Today
9/28/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MNPR
Fax
N/A
Employees
11
Year Founded
2014

Price Target and Rating

Average Stock Price Forecast
$11.33
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+1,862.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-10,520,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.78 per share

Miscellaneous

Free Float
8,268,000
Market Cap
$8.18 million
Optionable
Not Optionable
Beta
0.93

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Chandler D. Robinson M.B.A. (Age 39)
    M.D., M.Sc., MBA, MSc, Co-Founder, CEO, Pres & Director
    Comp: $708.12k
  • Ms. Kim R. Tsuchimoto CPA (Age 60)
    CFO, Sec., Treasurer & Director
    Comp: $350.55k
  • Mr. Andrew J. Cittadine M.B.A. (Age 51)
    Chief Operating Officer
    Comp: $390.41k
  • Dr. Patrice P. Rioux M.D. (Age 72)
    Ph.D., Acting Chief Medical Officer













MNPR Stock - Frequently Asked Questions

Should I buy or sell Monopar Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MNPR shares.
View MNPR analyst ratings
or view top-rated stocks.

What is Monopar Therapeutics' stock price forecast for 2023?

5 Wall Street analysts have issued twelve-month price targets for Monopar Therapeutics' stock. Their MNPR share price forecasts range from $2.00 to $24.00. On average, they expect the company's share price to reach $11.33 in the next twelve months. This suggests a possible upside of 1,862.5% from the stock's current price.
View analysts price targets for MNPR
or view top-rated stocks among Wall Street analysts.

How have MNPR shares performed in 2023?

Monopar Therapeutics' stock was trading at $2.37 at the beginning of the year. Since then, MNPR shares have decreased by 75.6% and is now trading at $0.5775.
View the best growth stocks for 2023 here
.

Are investors shorting Monopar Therapeutics?

Monopar Therapeutics saw a decline in short interest in September. As of September 15th, there was short interest totaling 64,700 shares, a decline of 33.0% from the August 31st total of 96,600 shares. Based on an average daily trading volume, of 250,500 shares, the days-to-cover ratio is currently 0.3 days. Approximately 1.1% of the company's shares are short sold.
View Monopar Therapeutics' Short Interest
.

When is Monopar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our MNPR earnings forecast
.

How were Monopar Therapeutics' earnings last quarter?

Monopar Therapeutics Inc. (NASDAQ:MNPR) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.03.

What other stocks do shareholders of Monopar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST).

When did Monopar Therapeutics IPO?

(MNPR) raised $9 million in an initial public offering on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager.

What is Monopar Therapeutics' stock symbol?

Monopar Therapeutics trades on the NASDAQ under the ticker symbol "MNPR."

How do I buy shares of Monopar Therapeutics?

Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Monopar Therapeutics' stock price today?

One share of MNPR stock can currently be purchased for approximately $0.58.

How much money does Monopar Therapeutics make?

Monopar Therapeutics (NASDAQ:MNPR) has a market capitalization of $8.18 million. The company earns $-10,520,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

Does Monopar Therapeutics have any subsidiaries?
The following companies are subsidiares of Monopar Therapeutics: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.
Read More
How can I contact Monopar Therapeutics?

Monopar Therapeutics' mailing address is 1000 SKOKIE BLVD SUITE 350, WILMETTE IL, 60091. The official website for the company is www.monopartx.com. The company can be reached via phone at 847-388-0349 or via email at info@monopartx.com.

This page (NASDAQ:MNPR) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -